Skip to main content

hsp90 inhibitor xl888

Generic: Hsp90 Inhibitor XL888

hsp90 inhibitor xl888: 2 clinical trials tracked.

hsp90 inhibitor xl888 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hsp90 inhibitor xl888, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

MelanomaSkin Cancer

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trials (2)

Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies

NCT03095781·Phase 1
Completed

Primary endpoint: Recommended Phase II Dose of the Combination of XL888 and Pembrolizumab as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Interventionalopen47 enrolledStarted 2017-07Completion 2021-063 sites · United StatesEmory University

Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT02721459·Phase 1
Active, not recruiting

Primary endpoint: Maximum Tolerated Dose (MTD)

Interventionalopen26 targetStarted 2016-09Completion 2026-111 site · United StatesH. Lee Moffitt Cancer Center and Research Institute